-
Mashup Score: 1The OncoAlert Newsletter is NOW OUT Click to Register - 2 day(s) ago
The OncoAlert Newsletter is now out for June 23-29, 2023
Source: www.OncoAlert360.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1The OncoAlert Newsletter is NOW OUT Click to Register - 2 day(s) ago
The OncoAlert Newsletter is now out for June 23-29, 2023
Source: www.OncoAlert360.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5
PURPOSE Datopotamab deruxtecan (Dato-DXd) is an antibody-drug conjugate consisting of a humanized antitrophoblast cell-surface antigen 2 (TROP2) monoclonal antibody linked to a potent, exatecan-derived topoisomerase I inhibitor payload via a plasma-stable, selectively cleavable linker. PATIENTS AND METHODS TROPION-PanTumor01 (ClinicalTrials.gov identifier: NCT03401385) is a phase I, dose-escalation, and dose-expansion study evaluating Dato-DXd in patients with previously treated solid tumors. The primary study objective was to assess the safety and tolerability of Dato-DXd. Secondary objectives included evaluation of antitumor activity and pharmacokinetics. Results from patients with advanced/metastatic hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) breast cancer (BC) or triple-negative BC (TNBC) are reported. RESULTS At data cutoff (July 22, 2022), 85 patients (HR+/HER2– BC = 41, and TNBC = 44) had received Dato-DXd. The objective response rate
Source: ascopubs.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6Neuroendocrine neoplasms of the ovary: a review of 63 cases - 4 day(s) ago
Objective To describe the clinicopathological characteristics and survival outcomes of ovarian neuroendocrine neoplasms from a curated registry. Methods This is a retrospective cross-sectional study of patients in our registry with confirmed ovarian neuroendocrine neoplasms. We excluded patients with small cell carcinoma not otherwise specified, small cell hypercalcemic type, and those with neuroendocrine ‘features’ or ‘differentiation.’ Clinicopathological characteristics were described in two separate groups: patients with carcinoid tumors and patients with neuroendocrine carcinomas. Progression-free and overall survival were estimated with the Kaplan-Meier product-limit estimator in these two groups, and multivariable analysis was done to identify predictors of survival for neuroendocrine carcinomas only. Results A total of 63 patients met inclusion criteria, 13 (21%) with carcinoid tumors and 50 (79%) with neuroendocrine carcinomas. In the carcinoid tumor group, one patient (8%) wa
Source: ijgc.bmj.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 20The OncoAlert ASCO 5k Registration - 4 day(s) ago
Registration for the OncoAlert ASCO 5k to be held on June 1st, 2024 at 7am local time and will start at the Hyatt Regency McCormick place, up to Chicago Harbour and ending at the starting place
Source: oncoalert.m-pages.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3
EGFR is often found to be constitutively activated in human cancer. Dobersberger et al. develop an engineering strategy for the generation of binding domains specifically recognizing ligand-activated EGFR. Incorporation of these binders into CAR molecules allows for specific targeting of the activated state of EGFR with CAR T cells.
Source: www.cell.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 59The 2023 OncoAlert Colloquium (GU Oncology) - 5 day(s) ago
DAY 1 (GU Oncology)February 5, 2024 Start 6pm CET 12 noon EST6pm-6:20 (CET)12 noon-12:20 (EST)Gilberto Morgan (20 min) FDA Approvals in Oncology, OncoAlert …
Source: www.youtube.comCategories: General Medicine News, Onc News and JournalsTweet-
A warm welcome to The OncoAlert Colloquium in partnership with @ASTRO_org @ESSOnews @ESGO_society @CancerCareMASCC @SIOGorg & OncoAlert🚨Global Consortium Top of GU Oncology https://t.co/1Zl5VJEGoa Top of Lung Oncology & Supportive Care https://t.co/Qb3lSbAKnN Top of Breast… https://t.co/HYAkf0GkCb https://t.co/XE41R8XD0I
-
-
Mashup Score: 1The OncoAlert Newsletter is NOW OUT Click to Register - 6 day(s) ago
The OncoAlert Newsletter is now out for June 23-29, 2023
Source: www.OncoAlert360.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 20The OncoAlert ASCO 5k Registration - 6 day(s) ago
Registration for the OncoAlert ASCO 5k to be held on June 1st, 2024 at 7am local time and will start at the Hyatt Regency McCormick place, up to Chicago Harbour and ending at the starting place
Source: oncoalert.m-pages.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 20The OncoAlert ASCO 5k Registration - 7 day(s) ago
Registration for the OncoAlert ASCO 5k to be held on June 1st, 2024 at 7am local time and will start at the Hyatt Regency McCormick place, up to Chicago Harbour and ending at the starting place
Source: oncoalert.m-pages.comCategories: General Medicine News, Onc News and JournalsTweet
RT @BenWestphalen: Out today 💥 The new @OncoAlert 🚨 #newsletter - if you don’t want to miss out: register at https://t.co/AxMKHsMAQC 🌐